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Background: The effects of paclitaxel-eluting balloon (PEB) on flow limiting intact plaques, healing processes and plaque remodeling at long term are not known. Aim of this exploratory study was to assess the long-term coronary arterial response to DEB using serial VH-IVUS. Methods: Patients with de novo significant A/B lesion type in vessels with diameter > 2,5mm and £ 3,5mm were enrolled. Major exclusion criteria were in-stent restenosis and STEMI patients. Lesion of interest was predilated and then treated with PEB (Dior, Eurocor) with a RVD/balloon diameter ratio of 1. Patients who received bailout stenting were excluded. VH-IVUS data were acquired before the predilation and at 4-month FU. Primary objective was to assess the change in % atheroma volume (PAV) and necrotic core (NC) volume from baseline to FU in the entire lesion. Secondary objectives were change from baseline in: VH plaque type, lumen area (LA) and plaque burden at the MLA site. Results: A total of 23 were screened, but eventually18 patients were enrolled in the study. Mostly, the target vessel was RCA (66.7% of cases). Mean DEB diameter and length were 3AE0.41 and 19.3AE3.9 respectively. Serial IVUS data at baseline and at 4-month FU are reported in Table 1 . In the entire lesion, PAV and NC volume did not change significantly, while at the MLA site, LA increased and plaque burden diminished as a result of a significant increase in EEM area. Remodeling index changed from 0.93AE0.17 to 1.09AE0.17 (p 0.00019). VH Thin Capped Fibroatheromas (TCFAs) significantly decreased from 7 to 2 changing into more stable plaque phenotypes (ThCFA and PIT).
Conclusions: PCI with DEB was not associated with a significant change in PAV and NC volume over time. However, TCFAs changed their phenotype into a more stable looking one. This hypothesis generating study might serve as a basis for exploring further the plaque sealing concept in a larger study.
TCT-591
Stent coverage and neointimal maturity in a randomized trial of limus-eluting stents with biodegradable polymer versus permanent polymer coatings assessed by optical coherence tomography Deutsches Herzzentrum, Munich, Munich, Germany Background: We hypothesized that biodegradable polymer siroimus-eluting stents (BP-SES) might enhance vascular healing as compared to permanent polymer everolimus-eluting stents (PP-EES). Accordingly we compared the healing patterns of BP-SES (OsiroÒ) with PP-EES (XienceÒ) using optical coherence tomography (OCT). Methods: A total of 60 patients undergoing coronary intervention for de novo stenoses were randomly assigned to BP-SES or PP-EES in 1:1 allocation. Tissue coverage, stent apposition and neointimal maturity were assessed using OCT at 6-8 months.
Results: Both stents showed marked heterogeneity in vascular healing. After adjustment for strut-level clustering with a mixed linear model approach, there were no statistical differences in the rates of uncovered struts between BP-SES and PP-EES (8.3% [95%CI: 0.6-56.8%] vs. 3.9% [95%CI: 0-81.7%] in PP-EES, p¼.41, Figure A) . A total of 0.1% of struts were malapposed in BP-SES group and 0.4% of struts in PP-EES group (p¼.42). In patient-level analysis, 2 patients in BP-SES group versus 3 in PP-EES group had >30% of uncovered struts, respectively (p¼.52). Neointimal volume obstruction was 8.8% [5.8-14 .0] in BP-SES versus 11.2% [8.0-23.5] in PP-EES (p¼.15, Figure B) . Conclusions: No significant differences in tissue coverage were detected by OCT between BP-SES and PP-EES. Marked heterogeneity of healing was observed in both groups.
TCT-592
Incidence, imaging and clinical outcomes of acute scaffold disruption and late structural discontinuity after implantation of the Absorb everolimus-eluting fully bioresorbable vascular scaffold: Optical coherence tomography assessment in the ABSORB Cohort B trial Associate Professor, University of Auckland Medical School, Auckland, New Zealand Background: Fully bioresorbable scaffolds (BRS) are a novel approach of treatment for coronary narrowing that provides transient vessel support with drug delivery capability without the long-term limitations of metallic drug-eluting stents. However, a potential drawback of the bioresorbable scaffold is the potential for disruption of the strut network when over-expanded. Conversely, the structural discontinuity of the polymeric struts at a late stage is a biologically programmed fate of the scaffold during the course of bioresorption. Methods: The ABSORB Cohort B trial is a multicentre single-arm trial assessing the safety and performance of the Absorb BVS (second generation, Abbott Vascular, www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
